Business Description
aTyr Pharma Inc
NAICS : 325414
SIC : 2836
ISIN : US0021201035
Description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.67 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.23 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.3 | |||||
| Beneish M-Score | 13.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -81.7 | |||||
| 3-Year EBITDA Growth Rate | 15.3 | |||||
| 3-Year EPS without NRI Growth Rate | 19 | |||||
| 3-Year FCF Growth Rate | 25.6 | |||||
| 3-Year Book Growth Rate | -20.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 60.96 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 604.81 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.43 | |||||
| 9-Day RSI | 68.58 | |||||
| 14-Day RSI | 69.43 | |||||
| 6-1 Month Momentum % | 31.95 | |||||
| 12-1 Month Momentum % | 99.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.63 | |||||
| Quick Ratio | 7.63 | |||||
| Cash Ratio | 6.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -79.1 | |||||
| Shareholder Yield % | -12.74 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -10633.5 | |||||
| Net Margin % | -9846.43 | |||||
| FCF Margin % | -10892.69 | |||||
| ROE % | -62.75 | |||||
| ROA % | -48.44 | |||||
| ROIC % | -341.07 | |||||
| 3-Year ROIIC % | -261.22 | |||||
| ROC (Joel Greenblatt) % | -454.89 | |||||
| ROCE % | -59.19 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 337.05 | |||||
| PB Ratio | 3.05 | |||||
| Price-to-Tangible-Book | 3.05 | |||||
| EV-to-EBIT | -3.01 | |||||
| EV-to-Forward-EBIT | -2.62 | |||||
| EV-to-EBITDA | -3.14 | |||||
| EV-to-Forward-EBITDA | -2.62 | |||||
| EV-to-Revenue | 319.98 | |||||
| EV-to-Forward-Revenue | 10.22 | |||||
| EV-to-FCF | -2.96 | |||||
| Price-to-Net-Current-Asset-Value | 3.84 | |||||
| Price-to-Net-Cash | 4.7 | |||||
| Earnings Yield (Greenblatt) % | -33.22 | |||||
| FCF Yield % | -25.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATYR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
aTyr Pharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.588 | ||
| EPS (TTM) ($) | -0.91 | ||
| Beta | 1.13 | ||
| Volatility % | 86.1 | ||
| 14-Day RSI | 69.43 | ||
| 14-Day ATR ($) | 0.230798 | ||
| 20-Day SMA ($) | 3.12325 | ||
| 12-1 Month Momentum % | 99.11 | ||
| 52-Week Range ($) | 1.0801 - 3.68 | ||
| Shares Outstanding (Mil) | 75.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
aTyr Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
aTyr Pharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
aTyr Pharma Inc Frequently Asked Questions
What is aTyr Pharma Inc(ATYR)'s stock price today?
The current price of ATYR is $3.30. The 52 week high of ATYR is $3.68 and 52 week low is $1.08.
When is next earnings date of aTyr Pharma Inc(ATYR)?
The next earnings date of aTyr Pharma Inc(ATYR) is 2025-02-08 Est..
Does aTyr Pharma Inc(ATYR) pay dividends? If so, how much?
aTyr Pharma Inc(ATYR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers